NAUT Nautilus Biotechnology Inc

$NAUT Held for 2 days. Sold at that 1.75 pump a little above the 200ma. Multi day continuation it breaks 200ma

$NAUT keeps pushing further than a lot of people expected. That's the kind of follow-through that tells you real money is still stepping in, not just a one-day pop. Worth keeping on the radar. 👀

$NAUT Very attractive asset. Could be easily bolted-on to another life science co, with near term products.

$NAUT agreed, today will be come consolidation and then anothe big leg up, short squeeze PT....new stock price upgrades by quite a bit, now avg at $4 - this checks all the boxes. $GPUS $LGHL $GCTK

$NAUT Buying the dip here again, looking for a swing above $2. Good earnings, good news and great price target => Sep-29-26 Initiated Roth Capital Buy $3.50

$NAUT keeps building a quieter kind of strength, the type that doesn't scream for attention but holds up. That's usually when we are accumulating before the crowd notices. Watching this on our scanners.

$NAUT Exactly, more coming here. Two new analysts just dropped $4 price targets and a buy alert. Im issuing a bu alert to my followers here at $1.42 - This is the safest play on the market with high reward. $CPOP $BIYA $TGE

🚀 Stock Watch Today: NAUT & QSI $NAUT (Nautilus Biotechnology) Bullish TA: Strong momentum today with shares up around 9% and trading near the daily high. Volume is running well above average, indicating strong buying interest. Analyst consensus remains Strong Buy with price targets significantly above the current share price. AI Score: 8.3/10 (Bullish) ✅ Strong volume expansion ✅ Positive analyst sentiment ✅ Improving commercialisation story ⚠️ Small-cap biotech volatility remains high Bull Target: $1.35-$1.50 Risk Level: High $QSI (Quantum-Si) Bullish TA: Strong breakout attempt with shares up roughly 13% today. Recent positive updates on the Proteus platform and protein sequencing milestones are supporting momentum. Trading above recent support with increasing volume. AI Score: 8.0/10 (Bullish Speculative) ✅ Strong momentum move ✅ Positive technology developments ✅ Large upside versus analyst targets ⚠️ Pre-revenue/high-risk growth profile

$NAUT handle forming on the cup. Bullish technical pattern if you believe in that sort of thing.

$NAUT this one is very bouncy, catching the dip here, has legs and momentum to pass $3 today on one of these spikes. All in here. Curling here for a big rebound. $MI $FNGR $SCKT

$NAUT ✅📈 Proteomics gets quoted as a $20 billion plus market, fragmented, with some estimates up around $70 to $80 billion later in the decade. Could be bigger. Nautilus is not trying to take all of it. The wedge is proteoforms, the specific modified versions of proteins that actually control biology, which mass spec and affinity platforms mostly blur together. Their tau paper showed 130 tau proteoform groups at scale, and the same approach is now going at Parkinson’s and AKT1. If you can measure that, every Alzheimer’s and oncology program that was only looking at total protein has to rethink

$NAUT — off the floor. Rel vol 4.8x. Nautilus is a proteomics name still pre-commercial. Single-molecule protein counting. The product is Voyager — pre-orders early 2027, instruments mid-2027. First revenue already printed: $190K, grant plus an early-access customer. Tau proteoform work landed in Nature Methods. Leerink initiated Outperform with a $4 target on Sep 9. Cap $142M. The balance sheet is the other half. Cash and investments were $129M at June 30 ($84M short-term). Runway into early 2028. They also filed a $125M ATM and a $300M shelf. That is capacity, not shares sold — but it is the overhang. Tape today: $1.12 (+16%) on 3.5M shares, rel vol 4.8x. Options volume ~560% of normal. Float 63M. Short 6%. 52-week low was $0.80. Price is bouncing that floor and walking into ~$1.20 resistance. Next print Nov 3. Simple read: washed-out proteomics name, cash covers the wait, $4 Street target vs a $1 tape. $1.00 is the line. $1.20 is the lid. NFA

$NAUT (Nautilus Biotechnology) is breaking a multi-week base on the daily chart: • Structural Intersection: After the decline from the $3.20–$3.40 region, price compressed inside a tight $0.84–$1.05 box. Wednesday’s surge through $1.05, on expanding volume, is the first clean resolution of that range to the upside. • Key Support Zone: The $0.92–$0.98 area (prior range high turned support) is the demand floor. A sustained hold above $1.00 keeps the breakout structure intact. • Asymmetric Projection: With risk defined against the $0.84 base, a hold above $1.12 opens a measured path toward the $1.70–$1.80 zone (~+61%). Small-cap biotech coming out of a washed-out range. Breakout only counts if the box holds as support. NFA / DYOR

$NAUT proven disruptive tech, ramp up 2027, but dilluation incoming after good news acc. to management.

$NAUT Another morning spike followed by a dropping tail for the day. I'll trade thst. No one wants to leave their money sitting in this over the weekend. They're looking for a Monday mover to stash their cash in over the weekend, no?

$NAUT I mean; why sell yet? Bios are hot right now. IPO’d at $10. Rushed to $25. Everything seem legit. If all works. $3.00 should hold fine once it gets there.

$NAUT holding its range quietly while the chart builds a base, no wild swings, just steady footing. That kind of calm price action is often the setup smart money loves before the next leg, and regular investors can watch it unfold right alongside them. 📈 🔥

$NAUT And how soon? "Because the Iterative Mapping approach is a foundational method, its validation opens the door to rapid expansion. Nautilus has already outlined a roadmap extending this system to α-synuclein for Parkinson’s disease and AKT1 in oncology, aiming for roughly 20 disease-focused assays by mid-2028."

$NAUT What can Voyager do? "Voyager’s flow cells are engineered to accommodate up to 10 billion intact protein molecules simultaneously. This massive array provides an exceptionally wide dynamic range, allowing researchers to measure both highly abundant and incredibly rare proteoforms in a single run without depleting high-abundance proteins"

$NAUT Did they just cancel the offering?? If they did this is a real good thing... Real good but I'm not sure yet.. News out 📰📰🤔🤔